NEW ANTIPLATELET DRUGS (PART 1)

QR Code

NEW ANTIPLATELET DRUGS (PART 1)

Antiplatelet agents are a necessary component of modern atherosclerosis therapy. The difficulties of antiplatelet treatment lie in the balance between the necessary therapeutic effect of the drug and the risk of excessive action leading to the bleeding. Possibility to control pharmacodynamics effect...

Full description

Saved in:

Bibliographic Details
Main Author:	A. B. Sumarokov
Format:	Article
Language:	English
Published:	Столичная издательская компания 2016-01-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	disaggregants prasugrel ticagrelor elinogrel thromboxane receptor inhibitors thrombin receptor inhibitors
Online Access:	https://www.rpcardio.online/jour/article/view/704
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

NEW ANTIPLATELET DRUGS. PART 2
by: A. B. Sumarokov
Published: (2016-01-01)

P2Y<sub>12</sub> Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel
by: N. M. Vorobyeva
Published: (2019-01-01)

Cost analysis of dual antiplatelet therapy with prasugrel and ticagrelor in patients with acute coronary syndrome after percutaneous coronary intervention
by: I. N. Dyakov, et al.
Published: (2020-09-01)

Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice?
by: T. M. Uskach, et al.
Published: (2020-12-01)

Double antiplatelet therapy in patients with acute coronary syndrome
by: A. V. Rodionov, et al.
Published: (2011-10-01)

Use of antiplatelet agents in patients after myocardial infarction followed up in Moscow outpatient clinics. Results of a non-interventional prospective study
by: A. I. Sapina, et al.
Published: (2024-04-01)

Choice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention
by: A. N. Golosova, et al.
Published: (2020-08-01)

Clopidogrel in the treatment of patients with ST-elevation acute myocardial infarction: state-of-art in 2013
by: O. V. Averkov
Published: (2013-02-01)

Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety
by: Fadel Bahouth, et al.
Published: (2025-05-01)

ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES
by: Z. M. Safiullina, et al.
Published: (2015-09-01)

Increase in the constrictor effects of Rho-kinase in skeletal muscle and coronary arteries of rats with chronic hypothyroidism
by: D. K. Gaynullina, et al.
Published: (2018-12-01)

Early discontinuation of dual antiplatelet therapy via acetylsalicylic acid cessation in patients with acute coronary syndrome undergoing percutaneous coronary interventions to reduce the bleeding risk
by: O. V. Averkov
Published: (2021-02-01)

Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT 5)
by: S. N. Tereshchenko, et al.
Published: (2019-11-01)

The Impact of the Fibrinolytic System on the Outcomes of Thrombolytic Therapy
by: R. E. Kalinin, et al.
Published: (2025-01-01)

Dynamics of hemostasis system parameters in assessing the risk of complications in the patients with acute myocardial infarction receiving antiplatelet therapy
by: T. R. Gvindzhiliya, et al.
Published: (2024-09-01)

Antiplatelet medications in acute coronary syndromes and percutaneous coronary interventions: focus on tirofiban
by: T. A. Batyraliev, et al.
Published: (2008-12-01)

Additional evidence against widespread use of inpatient antiplatelet therapy in coronavirus infection: data from a randomized controlled trial
by: I. S. Yavelov
Published: (2022-02-01)

Efficacy and safety of levilimab in the treatment of rheumatoid arthritis in real-life clinical practice: first results of the HELIOS observational study
by: A. M. Lila, et al.
Published: (2024-06-01)

High efficacy and retention rate of levilimab in the treatment of patients with rheumatoid arthritis in real-life practice
by: A. I. Zagrebneva, et al.
Published: (2025-03-01)

Anticoagulants: dose control methods and inhibitors
by: V. O. Bitsadze, et al.
Published: (2022-05-01)

Acid Suppressive Drugs
by: Cheol Min Shin
Published: (2022-06-01)

Chronic heart failure with preserved ejection fraction: optimal therapy. Literature review
by: A. A. Kuzmenko, et al.
Published: (2022-10-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT
by: S. Yu. Martsevich
Published: (2015-09-01)

The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention
by: A. S. Tereshchenko, et al.
Published: (2019-05-01)

AN ISSUE OF DRUG INTERACTION IN CARDIOLOGICAL PRACTICE: WHAT SHALL PHYSICIAN BE AWARE OF?
by: E. I. Tarlovskaya, et al.
Published: (2015-12-01)

Inflammation role in atrial fibrillation pathogenesis
by: A. I. Tarzimanova, et al.
Published: (1970-01-01)

Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patients in the USA
by: Benjamin Lowentritt, et al.
Published: (2025-05-01)

Inhibition of glucocorticoid-induced REDD1 expression by rapamycin in breast cancer cells
by: D. D. Grigorieva, et al.
Published: (2022-03-01)

Treatment of Patients with COVID-19 and Concomitant Cardiovascular Diseases: Do not Forget About the Principles of Evidence-based Medicine
by: S. Yu. Martsevich
Published: (2020-05-01)

INACTIVATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM. WHICH CLASS OF ANTIHYPERTENSIVE MEDICINE PRODUCTS TO PREFER?
by: S. V. Stolov
Published: (2020-12-01)

Investigating the role of the mPGES-PGE₂-EP4 pathway in Escherichia coli-induced mastitis in dairy cows: insights for non-antibiotic therapeutic strategies
by: Xiaolin Yang, et al.
Published: (2025-07-01)

Significance and possible causes of hormone receptor expression loss in metastatic breast cancer. Phenotypic evolution of luminal <i>BRCA1</i>-associated breast cancer to triple negative subtype in lung metastasis and PARP inhibition strategy in early-line therapy
by: A. I. Stukan, et al.
Published: (2022-12-01)

ALTERNATIVE APPROACHES TO THE USE OF TWO COMPONENT ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: EVIDENCES, RECOMMENDATIONS AND REAL PRACTICE
by: S. R. Gilyarevskiy, et al.
Published: (2015-12-01)

PROLONGED DUAL ANTIPLATELET THERAPY AFTER MYOCARDIAL INFARCTION: WHAT THE RESULTS OF THE PEGASUS-TIMI 54 TRIAL SHOW
by: I. S. Yavelov
Published: (2017-09-01)

TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS
by: L. N. Malay, et al.
Published: (2016-01-01)

Differential effects of dual antiplatelet and dual antithrombotic therapy on hemostasis in chronic coronary syndrome patients: the DEFINE CCS study
by: Tony Haddad, et al.
Published: (2025-12-01)

Liver function effects of SGLT2 inhibitor and GLP‐1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of RECAP study)
by: Daisuke Tsuriya, et al.
Published: (2025-07-01)

ANGIOTENSIN II RECEPTOR ANTAGONISTS AND ACE INHIBITORS: OPTIMIZATION OF CHOICE FOR TREATMENT OF CARDIOVASCULAR DISEASES
by: E. M. Khurs, et al.
Published: (2016-01-01)

Suboptimal physician adherence to evidence‐based guidelines for managing cardiorenal comorbidities in diabetes care: A retrospective single‐center study in Taiwan
by: Zong‐Yu Shen, et al.
Published: (2025-08-01)

Emerging Clinical Perspectives of Immunotherapy in Triple Negative Breast Cancer: A Comprehensive Review
by: Sparshita Dey, et al.
Published: (2025-06-01)